NEOGENOMICS INC (NEO)
US64049M2098 - Common Stock
NEO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 118 industry peers in the Health Care Providers & Services industry. NEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NEO had negative earnings in the past year.
NEO had a negative operating cash flow in the past year.
In multiple years NEO reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
1.2 Ratios
NEO has a Return On Assets (-5.13%) which is in line with its industry peers.
NEO has a Return On Equity (-9.12%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.13% | ||
| ROE | -9.12% | ||
| ROIC | N/A |
ROA(3y)-4.66%
ROA(5y)-2.48%
ROE(3y)-8.18%
ROE(5y)-4.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NEO (41.80%) is better than 70.09% of its industry peers.
NEO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-2.11%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEO has more shares outstanding than it did 1 year ago.
NEO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NEO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.95 indicates that NEO is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.95, NEO is in line with its industry, outperforming 58.12% of the companies in the same industry.
NEO has a Debt/Equity ratio of 0.58. This is a neutral value indicating NEO is somewhat dependend on debt financing.
NEO has a Debt to Equity ratio (0.58) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.95 |
ROIC/WACCN/A
WACC7.34%
2.3 Liquidity
NEO has a Current Ratio of 7.48. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.48, NEO belongs to the best of the industry, outperforming 98.29% of the companies in the same industry.
A Quick Ratio of 7.22 indicates that NEO has no problem at all paying its short term obligations.
NEO has a Quick ratio of 7.22. This is amongst the best in the industry. NEO outperforms 98.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.48 | ||
| Quick Ratio | 7.22 |
3. Growth
3.1 Past
NEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.11%, which is quite impressive.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.27%.
NEO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.42% yearly.
EPS 1Y (TTM)91.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q77.78%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y10.01%
Revenue growth 5Y16.42%
Revenue growth Q2Q13.88%
3.2 Future
The Earnings Per Share is expected to grow by 72.89% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.20% on average over the next years. This is quite good.
EPS Next Y92.49%
EPS Next 2Y81.05%
EPS Next 3Y72.89%
EPS Next 5YN/A
Revenue Next Year11.16%
Revenue Next 2Y10.46%
Revenue Next 3Y10.2%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 108.85, NEO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEO is on the same level as its industry peers.
NEO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 108.85 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NEO's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NEO's earnings are expected to grow with 72.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y81.05%
EPS Next 3Y72.89%
5. Dividend
5.1 Amount
No dividends for NEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEOGENOMICS INC
NASDAQ:NEO (5/3/2024, 7:08:27 PM)
After market: 15.3 0 (0%)15.3
+0.58 (+3.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.95B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 108.85 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.13% | ||
| ROE | -9.12% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.48 | ||
| Quick Ratio | 7.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)91.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y92.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.27%
Revenue growth 3Y10.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y